US 12,331,120 B2
Antibodies against programmed death-ligand 1 and uses thereof
Dae Hee Kim, Seoul (KR); Eung-Suk Lee, Gwangwon-do (KR); Min Jung Kim, Gangwon-do (KR); Nara Tae, Gangwon-do (KR); and Jong Rip Choi, Gangwon-do (KR)
Assigned to SCRIPPS KOREA ANTIBODY INSTITUTE, Gangwon-Do (KR)
Appl. No. 17/441,914
Filed by SCRIPPS KOREA ANTIBODY INSTITUTE, Gangwon-do (KR)
PCT Filed Apr. 9, 2020, PCT No. PCT/KR2020/004854
§ 371(c)(1), (2) Date Sep. 22, 2021,
PCT Pub. No. WO2020/209645, PCT Pub. Date Oct. 15, 2020.
Claims priority of application No. 10-2019-0042501 (KR), filed on Apr. 11, 2019.
Prior Publication US 2022/0195049 A1, Jun. 23, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C12N 5/10 (2006.01); C12N 15/10 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2827 (2013.01) [A61K 39/3955 (2013.01); A61K 47/6849 (2017.08); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01)] 11 Claims
OG exemplary drawing
 
1. An antibody binding to PD-L1 or an antigen-binding fragment thereof, comprising:
a heavy-chain variable region comprising a heavy-chain CDR1 of SEQ ID NO: 1, a heavy-chain CDR2 of SEQ ID NO: 2, and a heavy-chain CDR3 of SEQ ID NO: 3, a light-chain variable region comprising a light-chain CDR1 of SEQ ID NO: 5, a light-chain CDR2 of SEQ ID NO: 6, and a light-chain CDR3 of SEQ ID NO: 7; or
a heavy-chain variable region comprising a heavy-chain CDR1 of SEQ ID NO: 1, a heavy-chain CDR2 of SEQ ID NO: 2, and a heavy-chain CDR3 of SEQ ID NO: 11, a light-chain variable region comprising a light-chain CDR1 of SEQ ID NO: 13, a light-chain CDR2 of SEQ ID NO: 6, and a light-chain CDR3 of SEQ ID NO: 7.